Novavax Stock News

BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Block & Leviton announces that a class action lawsuit has been filed against Novavax, Inc. (NASDAQ: NVAX) for potential securities law violations. Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/nvax.

(PR-inside.com) NEW YORK, NY / ACCESSWIRE / November 22, 2021 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than January 18, 2022 in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Novavax, Inc. ("Novavax") (NASDAQ:NVAX) between March 2, 2021 and October 19, 2021, inclusive (the "Class Period"). The lawsuit was filed in the United States District Court for the District of Maryland and alleges violations of the Securities Exchange Act of 1934. If you purchased ..

SAN FRANCISCO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Novavax, Inc. (NASDAQ: NVAX) investors with significant losses to submit your losses now .

(PR-inside.com) NEW ORLEANS, LA / ACCESSWIRE / November 22, 2021 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Bristol-Myers Squibb Company (NYSE:BMY) Class: Investors who received Contingent Value Rights ("CVRs") (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers'' acquisition of Celgene on November 20, 2019 Lead Plaintiff Motion Deadline: December 6, 2021 MISLEADING PROSPECTUS To learn more, visit https://www.ksfcounsel.com/cases/nyse-bmy/ Höegh LNG Partners LP (NYSE:HMLP) Class Period: 8/22/2019 - 7/27/2021 Lead Plaintiff Motion Deadline: December 27, 2021 SECURITIES FRAUD To learn more, visit https://www.ksfcounsel.com/cases/nyse-hmlp/ Novavax, ..

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming January 11, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Novavax, Inc. (Novavax or the Company) (NASDAQ: NVAX) securities between March 2, 2021 and October 19, 2021, inclusive (the Class Period). If you suffered a loss on your Novavax investments or would like to inquire about potentially pursuing clai

SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Novavax, Inc. (NASDAQ: NVAX) securities between March 2, 2021 and October 19, 2021, both dates inclusive (the Class Period) have until January 11, 2022 to seek appointment as lead plaintiff in Sinnathurai v. Novavax, Inc. , No. 21-cv-02910 (D. Md.). Commenced on November 12, 2021, the Novavax class action lawsuit charges Novavax and certain of its top executives with violations of the Securities Exchange Act of 1934.

Novavax''s vaccine candidate may soon reach commercialization.

NEW ORLEANS, Nov. 19, 2021 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:

Centre Allows Export Of 20Million Novavax Doses To Indonesia OdishaTV

(PR-inside.com) SAN FRANCISCO, CA / ACCESSWIRE / November 19, 2021 / Hagens Berman urges Novavax, Inc. (NASDAQ:NVAX) investors with significant losses to submit your losses now. Class Period: Mar. 2, 2021 - Oct. 19, 2021 Lead Plaintiff Deadline: Jan. 11, 2022 Visit: www.hbsslaw.com/investor-fraud/NVAX Contact An Attorney Now: [email protected] 844-916-0895 Novavax, Inc. (NVAX) Securities Fraud Class Action: The lawsuit alleges that Defendants misrepresented Novavax''s progress toward successfully developing its COVID-19 vaccine (NVX-CoV2373), including: (1) overstating Novavax''s manufacturing capabilities and downplaying manufacturing issues that would impact the approval timeline for NVX-CoV2373; (2) concealing that Novavax was unlikely to meet its anticipated EUA regulatory timelines; (3) exaggerating the regulatory and commercial ..

NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than January 18, 2022 in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Novavax, Inc. (Novavax) (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the Class Period). The lawsuit was filed in the United States District Court for the District of Maryland and alleges violations of the Securities Exchange Act of 1934.

(PR-inside.com) BOSTON, MA / ACCESSWIRE / November 19, 2021 / The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Novavax, Inc. (NASDAQ:NVAX). The case is currently in the lead plaintiff stage. Investors who purchased NVAX securities between March 2, 2021 and October 19, 2021 may contact the Thornton Law Firm''s investor protection team by visiting www.tenlaw.com/cases/Novavax for more information. Investors may also email [email protected] or call 617-531-3917. FOR MORE INFORMATION: www.tenlaw.com/cases/Novavax The case alleges that Novavax and its senior executives made misleading statements to investors and failed to disclose that: (i) Novavax overstated ..

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming January 11, 2022 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Novavax, Inc. (Novavax or the Company) (NASDAQ: NVAX) securities between March 2, 2021 and October 19, 2021, inclusive (the Class Period). Investors suffering losses on their Novavax investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal righ

Novavax Inc. (NASDAQ:NVAX)s traded shares stood at 4.22 million during the last session, with the companys beta value hitting 1.33. At the close of trading, the stocks price was $191.05, to imply an increase of 3.84% or $7.06 in intraday trading. The NVAX shares 52-week high remains $331.68, putting it -73.61% down since that peak Novavax Inc. (NASDAQ: NVAX) Is Currently -73.61 Percent Below Its 52-Week High, But It Still Offers Strong Upside Potential. Read More »

Wall Street analysts expect Novavax, Inc. (NASDAQ:NVAX) to post earnings of $0.36 per share for the current quarter, according to Zacks. Four analysts have made estimates for Novavaxs earnings, with estimates ranging from ($4.95) to $7.89. Novavax posted earnings per share of ($2.70) in the same quarter last year, which suggests a positive year-over-year growth []